BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2889299)

  • 1. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic achlorhydria: for which diseases, when and for how long?].
    Koop H; Arnold R
    Dtsch Med Wochenschr; 1988 Mar; 113(13):516-8. PubMed ID: 2894969
    [No Abstract]   [Full Text] [Related]  

  • 5. Omeprazole: a comprehensive review.
    Massoomi F; Savage J; Destache CJ
    Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Powerful gastric acid inhibition: when is it justified?
    Dobrilla G; Amplatz S
    Ital J Gastroenterol; 1990; 22 Suppl 1():13-7. PubMed ID: 1983420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G; Sabbatini F; Mazzacca G
    Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
    [No Abstract]   [Full Text] [Related]  

  • 10. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug therapy of peptic ulcer. What is coming up?].
    Müller P; Dammann HG; Simon B; Kommerell B
    Leber Magen Darm; 1987 Feb; 17(1):50-4. PubMed ID: 3104707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Substituted benzimidazoles--a new dimension in ulcer therapy?].
    Fimmel CJ; Blum AL
    Wien Klin Wochenschr; 1984 Feb; 96(4):149-53. PubMed ID: 6324498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole: a new approach to gastric acid suppression.
    Buhl K; Clearfield HR
    Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical utility and safety of omeprazole.
    Walan A
    Scand J Gastroenterol Suppl; 1989; 166():140-4; discussion 145. PubMed ID: 2574908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 17. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of omeprazole in healing and prevention of reflux disease.
    Klinkenberg-Knol EC
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():27-30. PubMed ID: 1577392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.